Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Xia Wei, Xue Tan, Qinghu Guan, Ruizhi Zhang, Shiguang Lei & Shaofeng Wei. (2023) Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis. Human Vaccines & Immunotherapeutics 19:2.
Read now
Read now
Nijalingappa K. Kalappanavar, Apurba Ghosh, Monika Sharma, Latha Ravichandran, Nirmal Choraria, Saravanan P, Madhukar Pandey, Pradeep N, Prachee Shah, Sneha Nair, Ashfaque Shaikh & Serge van de Witte. (2022) Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in India. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Joyce H. S. You. (2021) Impact of COVID-19 infection control measures on influenza-related outcomes in Hong Kong. Pathogens and Global Health 115:2, pages 93-99.
Read now
Read now
Viviane Gresset-Bourgeois, Phillip S. Leventhal, Stéphanie Pepin, Rosalind Hollingsworth, Marie-Pierre Kazek-Duret, Iris De Bruijn & Sandrine I. Samson. (2018) Quadrivalent inactivated influenza vaccine (VaxigripTetra™). Expert Review of Vaccines 17:1, pages 1-11.
Read now
Read now
Riju Ray, Gaël Dos Santos, Philip O. Buck, Carine Claeys, Gonçalo Matias, Bruce L. Innis & Rafik Bekkat-Berkani. (2017) A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Human Vaccines & Immunotherapeutics 13:7, pages 1640-1652.
Read now
Read now
Pieter T. de Boer, Britt M. van Maanen, Oliver Damm, Bernhard Ultsch, Franklin C.K. Dolk, Pascal Crépey, Richard Pitman, Jan C. Wilschut & Maarten J. Postma. (2017) A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research 17:3, pages 249-265.
Read now
Read now
Anita J. Brogan, Sandra E. Talbird, Ashley E. Davis, Edward W. Thommes & Genevieve Meier. (2017) Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach. Human Vaccines & Immunotherapeutics 13:3, pages 533-542.
Read now
Read now
Ming-Chin Yang, Elise Chia-Hui Tan & Jian-Jhih Su. (2017) Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Human Vaccines & Immunotherapeutics 13:1, pages 81-89.
Read now
Read now
Articles from other publishers (25)
Yilin Gong, Xuelin Yao, Jin Peng, Yue Ma, Yu Fang, Kangkang Yan & Minghuan Jiang. (2023) Cost-Effectiveness and Health Impacts of Different Influenza Vaccination Strategies for Children in China. American Journal of Preventive Medicine 65:1, pages 155-164.
Crossref
Crossref
Clara R. Warmath, Ismael R. Ortega-Sanchez, Lindsey M. Duca, Rachael M. Porter, Molly G. Usher, Joseph S. Bresee, Kathryn E. Lafond & William W. Davis. (2023) Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review. Value in Health 26:5, pages 768-779.
Crossref
Crossref
Diana Tavares, Helena Mouriño, Cristina Antón Rodríguez & Carlos Martín Saborido. (2022) Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population. Vaccines 10:8, pages 1285.
Crossref
Crossref
Desmond Loong, Ba’ Pham, Mohammadreza Amiri, Hailey Saunders, Sujata Mishra, Amruta Radhakrishnan, Myanca Rodrigues, Man Wah Yeung, Matthew P. Muller, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults. Value in Health 25:8, pages 1439-1458.
Crossref
Crossref
Xuechen Xiong, Jing Li, Bo Huang, Tony Tam, Yingyi Hong, Ka-Chun Chong & Zhaohua Huo. (2022) Economic Value of Vaccines to Address the COVID-19 Pandemic in Hong Kong: A Cost-Effectiveness Analysis. Vaccines 10:4, pages 495.
Crossref
Crossref
Minghuan Jiang, Yilin Gong, Yu Fang, Xuelin Yao, Liuxin Feng, Shan Zhu, Jin Peng & Xinke Shi. (2022) Parental Preferences of Influenza Vaccination for Children in China: A National Survey with a Discrete Choice Experiment. International Journal of Environmental Research and Public Health 19:4, pages 2145.
Crossref
Crossref
Dawei Zhu, Min Lv, Yunhua Bai, Jiang Wu & Ping He. (2022) Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis. Vaccine 40:7, pages 994-1000.
Crossref
Crossref
Ling Tan, Xianhua Wu, Ji Guo & Ernesto D.R. Santibanez‐Gonzalez. (2021) Assessing the Impacts of COVID‐19 on the Industrial Sectors and Economy of China. Risk Analysis 42:1, pages 21-39.
Crossref
Crossref
Thomas D.J. de Haas, Karene Hoi Ting Yeung, Raymond Hutubessy, Ingeborg Maria van der Putten & E. Anthony S. Nelson. (2021) Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong. Vaccine 39:46, pages 6762-6780.
Crossref
Crossref
Timo Vesikari, Jos Nauta, Giulia Lapini, Emanuele Montomoli & Serge van de Witte. (2020) Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study. International Journal of Infectious Diseases 92, pages 29-37.
Crossref
Crossref
Chenyang Huang, Xiaofang Fu, Yuqing Zhou, Fenfang Mi, Guo Tian, Xiaoxiao Liu, Jie Wu, Cheng Ding, Danying Yan, Lanjuan Li & Shigui Yang. (2020) Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Vaccine 38:6, pages 1332-1344.
Crossref
Crossref
Minghuan Jiang, Pengchao Li, Weihua Wang, Mingyue Zhao, Naveel Atif, Shan Zhu & Yu Fang. (2020) Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China. Vaccine 38:5, pages 1057-1064.
Crossref
Crossref
Mu Yue, Borame L. Dickens, Joanne Su-yin Yoong, Mark I-Cheng Chen, Yot Teerawattananon & Alex R. Cook. (2019) Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study. Value in Health 22:12, pages 1345-1354.
Crossref
Crossref
Serge van de Witte, Jos Nauta, Emanuele Montomoli & Jos Weckx. (2018) A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses. Vaccine 36:40, pages 6030-6038.
Crossref
Crossref
José Antonio López Trigo, Rosa López Mongil, Alberto Mariano Lázaro, Gloria Mato Chaín, Norberto Moreno Villajos & Primitivo Ramos Cordero. (2018) Vacunación frente a la gripe estacional en las personas mayores. Evaluación de la vacuna tetravalente. Informe de posicionamiento. Revista Española de Geriatría y Gerontología 53, pages 185-202.
Crossref
Crossref
Ji Yun Noh, Won Suk Choi, Joon Young Song, Han Sol Lee, Sooyeon Lim, Jacob Lee, Yu Bin Seo, Jin-Soo Lee, Seong-Heon Wie, Hye Won Jeong, Jung Yeon Heo, Young Keun Kim, Kyung Hwa Park, Shin Woo Kim, Sun Hee Lee, Jung Hwa Lee, Dong Hyun Kim, Sung Il Woo, Chae Seung Lim, Kyung Soon Cho, Hee Jin Cheong & Woo Joo Kim. (2018) Significant circulation of influenza B viruses mismatching the recommended vaccine-lineage in South Korea, 2007–2014. Vaccine 36:35, pages 5304-5308.
Crossref
Crossref
Joyce H.S. You, Wai-kit Ming, Chak-fei Lee, Owen Tak-yin Tsang & Paul Kay-sheung Chan. (2018) Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong. Vaccine 36:31, pages 4610-4620.
Crossref
Crossref
Yik-Kei Chan, Rity YK Wong, Margaret Ip, Nelson LS Lee & Joyce HS You. (2016) Economic Outcomes of Influenza in Hospitalized Elderly with and without ICU Admission. Antiviral Therapy 22:2, pages 173-177.
Crossref
Crossref
Carlos Wong, Minghuan Jiang & Joyce H. S. You. (2016) Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children. PLOS ONE 11:12, pages e0169030.
Crossref
Crossref
Christiaan Dolk, Martin Eichner, Robert Welte, Anastassia Anastassopoulou, Laure-Anne Van Bellinghen, Barbara Poulsen Nautrup, Ilse Van Vlaenderen, Ruprecht Schmidt-Ott, Markus Schwehm & Maarten Postma. (2016) Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. PharmacoEconomics 34:12, pages 1299-1308.
Crossref
Crossref
Man-Kit Leung & Joyce H.S. You. (2016) Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly. Vaccine 34:22, pages 2469-2476.
Crossref
Crossref
Paul K.S. Chan, Wilson W.S. Tam, Tsz Cheung Lee, Kam Lun Hon, Nelson Lee, Martin C.W. Chan, Hing Yim Mok, Martin C.S. Wong, Ting Fan Leung, Raymond W.M. Lai, Apple C.M. Yeung, Wendy C.S. Ho, E. Anthony S. Nelson & David S.C. Hui. (2015) Hospitalization Incidence, Mortality, and Seasonality of Common Respiratory Viruses Over a Period of 15 Years in a Developed Subtropical City. Medicine 94:46, pages e2024.
Crossref
Crossref
Yukari Tsurudome, Kazuhiko Kimachi, Yusuke Okada, Kenta Matsuura, Yusuke Ooyama, Kayo Ibaragi, Yoichiro Kino & Kohji Ueda. (2015) Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan. Microbiology and Immunology 59:10, pages 597-604.
Crossref
Crossref
Carolien E van de Sandt, Rogier Bodewes, Guus F Rimmelzwaan & Rory D de Vries. (2015) Influenza B viruses: not to be discounted. Future Microbiology 10:9, pages 1447-1465.
Crossref
Crossref
Joon-Sup Yeom. (2015) Vaccination for Diabetic Patients: An Update. The Journal of Korean Diabetes 16:4, pages 236.
Crossref
Crossref